Neoplastic Brachial Plexopathy Medication

  • Author: Mark A Wren, MD, MPH; Chief Editor: Robert H Meier III, MD   more...
 
Updated: Jan 19, 2010
 

Medication Summary

No medications are specific for this diagnostic entity. Typical analgesic and adjunct analgesic agents may be worthwhile in managing neoplastic plexopathy.

Opioid analgesics (eg, long-acting oxycodone or fentanyl) are associated with fewer concerns about tolerance and dependency than many other opiates. A ceiling effect is also absent with these agents, while use of combination agents like hydrocodone/acetaminophen may be limited by maximum dose of acetaminophen allowable (4 g/d). Opiates may be effective at acceptable doses and often are tried first. For more mild symptoms, topical analgesics should be tried.

Nonsteroidal anti-inflammatory drugs (NSAIDs) can be helpful and usually are tried in conjunction with other agents.

Adjunct agents such as tricyclic antidepressants (eg, nortriptyline, amitriptyline) or other antidepressants (eg, sertraline, venlafaxine), anticonvulsants (Lyrica, gabapentin, Tegretol), and, less commonly, antiarrhythmics (eg, mexiletine) may be used for control of neuropathic pain.

Next

Opioid analgesic agents

Class Summary

Should be used early in the disease. As in most painful conditions, begin with low potency medications at low doses and taper to desired response.

Hydrocodone and acetaminophen (Vicodin, Lortab, Norcet)

 

Drug combination indicated for moderate to severe pain.

Oxycodone (OxyContin)

 

Indicated for the relief of moderate to severe pain.

Fentanyl (Duragesic)

 

Potent opioid analgesic with much shorter half-life than morphine sulfate. DOC for conscious sedation analgesia.

Excellent choice for pain management and sedation with short duration (30-60 min) and easy to titrate. Easily and quickly reversed by naloxone.

Previous
Next

Corticosteroids

Class Summary

Can be helpful since inflammation may be part of the pathophysiology of the pain of NBP, as previously mentioned.

Prednisone (Deltasone, Orasone, Meticorten)

 

May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Previous
Next

Cyclooxygenase-2 (COX-2) inhibitors

Class Summary

Although increased cost can be a negative factor, the incidence of costly and potentially fatal GI bleeds is clearly less with COX-2 inhibitors than with traditional NSAIDs. Ongoing analysis of cost avoidance of GI bleeds will further define the populations that will find COX-2 inhibitors the most beneficial.

Celecoxib (Celebrex)

 

Inhibits primarily COX-2. COX-2 is considered an inducible isoenzyme, induced during pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited; thus, GI toxicity may be decreased. Seek lowest dose for each patient.

Previous
Next

Nonsteroidal anti-inflammatory drugs

Class Summary

Have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclo-oxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions. Inexpensive older NSAIDs like ibuprofen or naproxen may be considered; however, COX-2 inhibitors with their lower GI toxicity are often first-line agents.

Ibuprofen (Motrin, Ibuprin)

 

DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Naproxen (Naprosyn, Naprelan, Anaprox)

 

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which results in a decrease of prostaglandin synthesis.

Previous
Next

Tricyclic antidepressants

Class Summary

A complex group of drugs that have central and peripheral anticholinergic effects, as well as sedative effects. They have central effects on pain transmission and block the active reuptake of norepinephrine and serotonin.

Amitriptyline (Elavil)

 

Analgesic for certain chronic and neuropathic pain. Used as adjunct therapy.

Nortriptyline (Pamelor, Aventyl HCl)

 

Used as adjunct therapy. Has demonstrated effectiveness in the treatment of chronic pain. Used as adjunct agent.

By inhibiting the reuptake of serotonin and/or norepinephrine by the presynaptic neuronal membrane, this drug increases the synaptic concentration of these neurotransmitters in the CNS.

Pharmacodynamic effects such as the desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to play a role in its mechanisms of action.

Previous
Next

Anticonvulsants

Class Summary

Use of certain antiepileptic drugs, such as the GABA analogue Neurontin (gabapentin), has proven helpful in some cases of neuropathic pain. Have central and peripheral anticholinergic effects, as well as sedative effects, and block the active reuptake of norepinephrine and serotonin. The multifactorial mechanism of analgesia could include improved sleep, altered perception of pain, and increase in pain threshold. Rarely should these drugs be used in treatment of acute pain, since a few weeks may be required for them to become effective.

Carbamazepine (Tegretol)

 

May reduce polysynaptic responses and block post-tetanic potentiation. Used as adjunct therapy.

Gabapentin (Neurontin)

 

Has anticonvulsant properties and antineuralgic effects; however, exact mechanism of action is unknown. Structurally related to GABA but does not interact with GABA receptors. There are no firm rules, but, in elderly patients, less potentially anticholinergic medications like gabapentin may be a good first choice. Used as adjunct therapy.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Mark A Wren, MD, MPH  Medical Director, Department of Physical Medicine and Rehabilitation, HealthSouth Rehabilitation Hospital of Texarkana

Mark A Wren, MD, MPH is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Robert J Kaplan, MD  James E Van Zandt VA Medical Center, Staff Physician, Department of Rehabilitation Medicine

Robert J Kaplan, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists, and Physiatric Association of Spine, Sports and Occupational Rehabilitation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Michael T Andary, MD, MS  Residency Program Director, Professor, Department of Physical Medicine and Rehabilitation, Michigan State University College of Osteopathic Medicine

Michael T Andary, MD, MS is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American Medical Association, and Association of Academic Physiatrists

Disclosure: allergan Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching

Kelly L Allen, MD  Regional Medical Director, IMX-Medical Management Services

Disclosure: Nothing to disclose.

Chief Editor

Robert H Meier III, MD  Director, Amputee Services of America; Active Medical Staff, Presbyterian/St Luke's Hospital, Spalding Rehabilitation Hospital, Select Specialty Hospital; Consulting Staff, Kindred Hospital

Robert H Meier III, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation and Association of Academic Physiatrists

Disclosure: Nothing to disclose.

References
  1. Kim DH, Murovic JA, Tiel RL. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg. Feb 2005;102(2):246-55.

  2. Siqueira MG, Martins RS, Teixeira MJ. Management of brachial plexus region tumours and tumour-like conditions: relevant diagnostic and surgical features in a consecutive series of eighteen patients. Acta Neurochir (Wien). Sep 2009;151(9):1089-98. [Medline].

  3. Kori SH, Foley KM, Posner JB. Brachial plexus lesions in patients with cancer: 100 cases. Neurology. Jan 1981;31(1):45-50. [Medline].

  4. Killer HE, Hess K. Natural history of radiation-induced brachial plexopathy compared with surgically treated patients. J Neurol. Jul 1990;237(4):247-50.

  5. Kamenova B, Braverman AS, Schwartz M, et al. Effective treatment of the brachial plexus syndrome in breast cancer patients by early detection and control of loco-regional metastases with radiation or systemic therapy. Int J Clin Oncol. Jun 2009;14(3):219-24. [Medline].

  6. Gerevini S, Mandelli C, Cadioli M, Scotti G. Diagnostic value and surgical implications of the magnetic resonance imaging in the management of adult patients with brachial plexus pathologies. Surg Radiol Anat. Mar 2008;30(2):91-101. [Medline].

  7. Cross NE, Glantz MJ. Neurologic complications of radiation therapy. Neurol Clin. Feb 2003;21(1):249-77. [Medline].

  8. Dumitru D. Brachial plexopathy and proximal mononeuropathies. In: Electrodiagnostic Medicine. Philadelphia:. Hanley & Belfus Inc;1995:585-642.

  9. Harper CM Jr, Thomas JE, Cascino TL, Litchy WJ. Distinction between neoplastic and radiation-induced brachial plexopathy, with emphasis on the role of EMG. Neurology. Apr 1989;39(4):502-6. [Medline].

  10. Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology. Mar 1999;210(3):807-14. [Medline].

  11. Kline DG, Judice DJ. Operative management of selected brachial plexus lesions. J Neurosurg. May 1983;58(5):631-49.

  12. Lachance DH, O''Neill BP, Harper CM Jr, et al. Paraneoplastic brachial plexopathy in a patient with Hodgkin''s disease. Mayo Clin Proc. Jan 1991;66(1):97-101.

  13. Liang R, Kay R, Maisey MN. Brachial plexus infiltration by non-Hodgkin''s lymphoma. Br J Radiol. Nov 1985;58(695):1125-7. [Medline].

  14. Meador KJ, Richards B, Hunter S, et al. Bibrachial palsy due to paraneoplastic encephalomyelitis. South Med J. Aug 1989;82(8):1053-5. [Medline].

  15. Mukherji SK, Castillo M, Wagle AG. The brachial plexus. Seminars in Ultrasound, CT and MRI. Semin Ultrasound CT MR. Dec 1996;17(6):519-38. [Medline].

  16. Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992;23(5):915-23. [Medline].

  17. Stewart JB. The brachial plexus. In: Focal Peripheral Neuropathies. New York, NY:. Raven Press Ltd;1993:111-140.

  18. Weber RJ. Rehabilitation issues in plexopathies. In: Physical Medicine and Rehabilitation. Philadelphia: WB Saunders Co:. 990-1001.

  19. Wilbourn AJ. Brachial plexus disorders. In: Peripheral Neuropathy, PDPTJE. Philadelphia:. WB Saunders Co;1993:911-50.

  20. Wilbourn AJ. Electrodiagnosis of plexopathies. Neurol Clin. Aug 1985;3(3):511-29. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.